Assessment of drug-drug interactions: Concepts and approaches

Xenobiotica

Volumn 31, Issue 8-9, 2001, Pages 499-538

  Weaver, R J ^a  

^a Servier Research and Development   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACYLTRANSFERASE; ALPRAZOLAM; CLARITHROMYCIN; CYTOCHROME P450; DIMETHYLANILINE MONOOXYGENASE; DRUG METABOLIZING ENZYME; ENZYME INHIBITOR; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; GLUCURONOSYLTRANSFERASE; ITRACONAZOLE; KETOCONAZOLE; LORNOXICAM; MIDAZOLAM; NEW DRUG; PHENPROCOUMON; SULFAMETHIZOLE; SULFAPHENAZOLE; SULFOTRANSFERASE; TENOXICAM; TERFENADINE; THEOPHYLLINE; TOLBUTAMIDE; TRIAZOLAM; WARFARIN;

ACCURACY; ARTICLE; CONCENTRATION RESPONSE; DRUG DESIGN; DRUG METABOLISM; ENZYME ACTIVE SITE; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MODEL; PREDICTION;

ANIMALS; CATALYTIC DOMAIN; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; DRUG INTERACTIONS; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITORS; HUMANS; KINETICS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING;

EID: 0034837148     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250110060950     Document Type: Article

References (211)

1. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting
2. The interaction of diltiazem with lovastatin and pravastatin
3. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines
4. Particular ability of cytochrome P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs
5. Drug interactions in palliative care
6. Inhibition by pentachlorophenol of the initiating and promoting activities of 1-hydroysafrole for the formation of enzyme-altered foci and tumors in rat liver
7. Paracetamol glucuronidation by recombinant rat and human phenol UDP-glycuronosyltransferases
8. Cytochrome P450 isoform inhibitors as a tool for the human liver microsomes
9. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae
10. UDP-glucuronosyltransferases
11. Genetic deficiency of bilirubin glucuronidation in rats and humans
12. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites
13. Human and rat liver phenol sulfotransferase: Structure-activity relationships for phenolic substrates
14. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans
15. Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450
16. Aspect n-glucuronidation of xenobiotics symposium. Species differences in n-glucuronidation
17. In vitro assessment of human cytochrome P450
18. Induction of microsomal enzymes by foreign chemicals and carcinogensis by polycyclic aromatic hydrocarbons: G. H. A. Clowes Memorial Lecture
19. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450
20. Further studies on the dissociation of the isosafrole metabolite-cytochrome P450 complex
21. Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture
22. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes
23. Triazolam disposition
24. Targeting anti-peptide antibodies towards P450 enzymes
25. Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: Role of the glucocorticoid and pregnane X receptors
26. Prediction of in vivo drug interaction from in vitro systems exemplified by interaction between verapamil and cimetidine using human liver microsomes and primary hepatocytes
27. Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: Relationship between UGT1A1 promoter genotype and variability in a liver bank
28. Validation of the five-drug 'Pittsburgh cocktail' approach for assessment of selective regulation of drug-metabolizing enzymes
29. Covalent binding to DNA mutagenicity of 2,4-diaminotoluene metabolites produced by isolated hepatocytes and 9000g supernatant from Fischer 344 rats
30. Effect of inhibitor depletion on inhibitory potency: Tight binding inhibition of CYP3A by clotrimazole
31. CYP4A1 gene transfection studies and the peroxisome proliferator-activated receptor: Development of a high-throughput assay to detect peroxisome proliferators
32. Evidence that CYP2C19 is the major (s)-mephenytoin 4′-hydroxylase in humans
33. UDP-glucuronosyltransferase inhibitors
34. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin
35. Effect of zileuton on theophylline pharmacokinetics
36. Monomorphic and polymorphic human arylamine N-acetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes
37. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3
38. Human cytochromes and some newer antidepressants: Kinetics, metabolism, and drug interactions
39. A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monooxygenases in human liver microsomes
40. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450
41. Mechanism-based inactivation of human liver microsomal cytochrome P450 IIIA4 by gestodene
42. In vitro techniques for studying drug metabolism
43. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects
44. Covalent modification of lysine during the suicide inactivation of rat liver cytochrome P-450 by chloramphenicol
45. The interaction of foreign chemical compounds with the glucuronidation of estrogens in vitro
46. Acetylator genotype and arylamine-induced carcinogenesis
47. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities
48. Terfenadine-ketoconazole interaction: Pharmacokinetics and electrocardiographic consequences
49. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
50. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model
51. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans
52. Heterogeneity of CYP3A isoforms metabolising erythromycin and cortisol
53. Mexiletine effects on theophylline disposition
54. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport
55. Effects of intestinal CYP3A4 and p-glycoprotein on oral drug absorption-theoretical approach
56. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
57. Epidemiology of drug-drug interactions as a cause of hospital admissions
58. Clinically significant drug interactions
59. Influences of pyridine and some pyridine derivatives on spectral properties of reduced microsomes and on microsomal drug metabolizing activity
60. m diazepam N-demethylases
61. Evaluation of drug interactions in intact hepatocytes: Inhibitors of terfenadine metabolism
62. Quantitiative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: Use of maximum unbound concentrations of inhibitor at the inlet to the liver
63. CYP3A4 Drug interactions: Correlation of 10 in vitro probe substrates
64. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men
65. Route of administration does not explain the lack of correlation between putative in vivo probes of cytochrome P4503A
66. Prediction of pharmacokinetic drug/drug interactions from in vitro data: Interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants
67. Identification of rifampin-inducible P450111A4 (CYP3A4) in human bowl enterocytes
68. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in human based on in vitro experiments
69. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites
70. Selective inhibition of sulfate conjugation in the rat: Pharmacokinetics and characterization of the inhibitory effect of 2,6-chloro-4-nitrophenol
71. Oxidation of midazolam and triazolam by human liver cytochrome P450 3A4
72. Use of general regression neural networks for determination of inhibitor/inducer activity of coadministered agents
73. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism
74. Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: Selective catalysis by FMO3
75. Characterization of CYP2C9 from human liver: Respective roles in microsomal tolbutamide, s-mephenytoin, and omeprazole hydroxylations
76. A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities
77. Metabolism of ketotifen by human liver microsomes. In vitro characterization of a tertiary ammonium glucuronide
78. Further concerns over Cheng-Prusoff analysis
79. Quaternary ammonium-linked glucuronides of amitriptyline, imipramine and chlorpromazine
80. A class of strong inhibitors of microsomal monooxygenases: The ellipticines
81. P450 substrate specificity and metabolism
82. Induction, regulation and inhibition
83. Preclinical evaluation of drug-drug interaction potential: Present status of the implication of primary human hepatocytes in the evaluation of cytochrome P450 induction
84. Inhibition and induction of cytochrome P450 and the clinical implications
85. The erythromycin breath test predicts the clearance of midazolam
86. Drug-metabolism research challenges in the new millennium. Individual variability in drug therapy and drug safety
87. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its n-dehydroxylated metabolite, abbott-66193
88. The UDP-glycosyltransferase gene super family: Recommended nomenclature update based on evolutionary divergence
89. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines
90. In vitro n-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes
91. Drug Interactions of HIV protease inhibitors
92. In vivo drug-drug interaction studies - A survey of all new molecular entities approved from 1987 to 1997
93. Biochemistry and molecular biology of drug-metabolizing sulfotransferase
94. Impact of mechanism-based enzyme inactivation on inhibitor potency: Implications for rational drug discovery
95. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture
96. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation
97. Identification of bilirubin UDP-GTs in the human alimentary tract in accordance with the gut as a putative metabolic organ
98. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s
99. Nonspecific binding of drugs to human liver microsomes
100. Use of pentachlorophenol as long-term inhibitor of sulfation of phenols and hydroxamic acids in the rat in vivo
101. Transport mechanisms for cationic drugs and proteins in kidney, liver and intestine: Implication for drug interactions and cell-specific drug delivery
102. The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro
103. Saquinavir interaction with midazolam: Pharmacokinetic considerations when prescribing protease-inhibitors for patients with HIV-disease
104. The use of caffeine as a metabolic probe for human drug metabolizing enzymes
105. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
106. Glucuronidation in vitro and in vivo: Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine
107. Comparison of the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat livers
108. Regulation of glucuronidation and sulphate conjugation in isolated hepatocytes
109. Dextromethorphan: Polymorphic serum patterns of the O-demethylated and didemethylated metabolites in man
110. Competition between conjugations for the same substrate
111. Glucuronidation
112. Sulfation
113. Complexation of cytochrome P450 isozymes in hepatic microsomes from SKF 525-A-induced rats
114. P450 enzymes: Inhibition mechanisms, genetic regulation and effects of liver disease
115. Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: Contribution of type I system
116. Contribution of flavin-containing monooxygenase and cytochrome P450 to imipramine N-oxidation in rat hepatic microsomes
117. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature
118. Lumping of whole body physiologically based pharmacokinetic models
119. Quantitative structure-pharmacokinetic relationships. II. Mechanistically based model for the relationship between the tissue distribution parameters and the lipophilicity of the compounds
120. Incorporating variability and uncertainty into the in vitro-in vivo prediction of hepatic clearance
121. Empirical versus mechanistic modelling: Comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetics relationship
122. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
123. Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine
124. Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol
125. The prediction of human pharmacokinetics parameters from preclinical and in vitro metabolism data
126. Development of an in vitro reporter gene assay to assess xenobiotic induction of the human CYP3A4 gene
127. A reporter gene assay to assess the molecular mechanisms of xenobiotic-dependent induction of the human CYP3A4 gene in vitro
128. A potentially hazardous interaction between erythromycin and midazolam
129. The xenobiotic inhibitor profile of cytochrome P4502C8
130. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes
131. Suicide inhibitors for drug metabolising enzymes: Mechanisms and biological consequences
132. Cytochrome P-450 1A1 expression in human small bowl: Interindividual variation and inhibition by ketoconazole
133. Kinetics of conjugation reactions in eliminating organs
134. Metabolism: Scaling-up from in vitro to organ and whole body
135. Relevance of induction of human drug-metabolising enzymes: Pharmacological and toxicological implications
136. Phenotyping of flavin-containing monooxydenase using caffeine metabolism and genotyping of FMO3 gene in a Korean population
137. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials
138. Biotransformation of xenobiotics
139. Dexamethazone enhances constitutive androstane receptor expression in human hepatocytes: Consequences on cytochrome P450 gene regulation
140. Self-induction by oleandomycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P450. Comparison with troleandomycin
141. Cyclosporin A drug interactions: Screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes
142. Kinetics and inhibition of the formation of 6(-naltrexol from naltrexone in human liver cytosol
143. Morphine glucuronidation in the rhesus monkey: A comparative in vivo and in vitro study
144. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors
145. Can caffeine metabolism be used as an in-vivo probe for human flavin-containing monooxgenase activity
146. Application of human liver microsomes in metabolism-based drug-drug interactions: In vitro-in vivo correlations and the Abbott Laboratories experience
147. Steric factors in the inhibitory interaction of imidazoles with microsomal enzymes
148. Important drug interactions in dermatology
149. Kinetics of drug interactions
150. Stereoselective sulfoxidation by human flavin-containing monooxygenase: Evidence for catalytic diversity between hepatic, renal and fetal forms
151. Sulfotransferases in a human colon carcinoma cell, caco-2
152. Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: Application to amitriptyline N-demethylation
153. Inhibition of human and rabbit liver steroid and xenobiotic UDP-glucuronosyltransferases by tertiary amine drugs - Implications for adverse drug reactions
154. Purification and characterization of an anticonvulsant-induced human cytochrome P-450 catalysing cyclosporin metabolism
155. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
156. Criteria for mechanism-based enzyme inactivation
157. Isolation and characterization of a novel quaternary ammonium-linked glucuronide of lamotrigine
158. N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism
159. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: A prospective study
160. N-acetylation of the heterocyclic amine batracylin by human liver
161. Benzydamine n-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity
162. Phenotyping of drug-metabolizing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes
163. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the 'Cooperstown' cocktail
164. Hydantoin and barbiturate inhibitors of CYP2C19 and CYP2C9, ISSX, Indianapolis, USA
165. Glucuronidation of zileuton (A-64077) by human hepatic microsomes
166. Interaction with p-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells
167. Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques
168. Inhibition of human hepatic cytochrome P4502E1 by azole antifungals. CNS-active drugs and non-steroidal anti-inflammatory agents
169. Inhibition selectivity of grapefruit juice components on human cytochromes P450
170. Inhibitors of cytochrome P450s and their mechanism of action
171. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-medicated metabolism
172. Prediction of in vivo midazolam clearance from hepatic CYP3A content and midazolam 1-hydroxylation activity in liver transplant patients
173. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro in correlations in liver transplant patients
174. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation
175. Acute inhibition of methadone metabolism by ritonavir: Projection of interindividual variability from in vitro data
176. Human UDP-glucuronosyltransferases: Metabolism, expression and disease
177. The pharmacological role of P-glycoprotein in the intestinal epithelium
178. P-glycoprotein system as a determinant of drug interactions: The case of digoxin-verapamil
179. Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine
180. Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole
181. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents
182. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and p-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
183. Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent
184. Metabolism of gestodene in human liver cytosol and microsomes in vitro
185. Erythromycin breath-test as an assay of glucocorticoid-inducible liver cytochromes P-450: Studies in rats and patients
186. Comparison of urinary 6β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity
187. Identification of an inducible form of cytochrome P-450 in human liver
188. Identification of glucocorticiod-inducible cytochrome P-450 in the intestinal mucosa in rats and man
189. Cytochrome P450 2C9 is responsible for hydroxylation of the naphthoquinone antimalarial drug 58C80 in human liver
190. Hydroxylation of the antimalarial drug 58C80 by CYP2C9 in human liver microsomes: Comparison with mephenytoin and tolbutamide hydroxylations
191. A comparison of basal and induced hepatic microsomal cytochrome P450 monooxygenase activities in the cynomologous monkey (Macaca fascicularis) and man
192. Acetylation
193. Structure-activity relationships in the effects of 1-alkylimidazoles on microsomal oxidation in vitro and in vivo
194. Pharmacokinetic drug interactions in anaesthetic practice
195. Inhibition of human CYP3A catalyzed 1-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine
196. The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies
197. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: Implication of concentrative uptake of inhibitors into liver
198. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver
199. Cytochrome P450 mediated metabolism of diazepam in human and rat: Involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner
200. Interaction between midazolam and clarithromycin: Comparison with azithromycin
201. Immunoquantitation of FMO1 in human liver, kidney, and intestine
202. The contribution of p-glycoprotein to pharmacokinetics drug-drug interactions
203. Formation of glucuronide, sulphate and glutathione conjugates of benzo[a]pyrene metabolites in hepatocytes isolated from inbred strains of mice
204. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans
205. Characterization of human small intestinal cytochromes P-450
206. Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies
207. Mechanisms, multiple forms and substrate specificities of flavin-containing mono-oxygenases